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Abstract
Introduction: Since alendronate became available in generic form in the Unites States in 2008, its price has been decreasing.
The objective of this study was to investigate the impact of alendronate cost on the cost-effectiveness of osteoporosis
screening and treatment in postmenopausal women.
Methods: Microsimulation cost-effectiveness model of osteoporosis screening and treatment for U.S. women age 65 and
older. We assumed screening initiation at age 65 with central dual-energy x-ray absorptiometry (DXA), and alendronate
treatment for individuals with osteoporosis; with a comparator of ‘‘no screening’’ and treatment only after fracture
occurrence. We evaluated annual alendronate costs of $20 through $800; outcome measures included fractures; nursing
home admission; medication adverse events; death; costs; quality-adjusted life-years (QALYs); and incremental cost-
effectiveness ratios (ICERs) in 2010 U.S. dollars per QALY gained. A lifetime time horizon was used, and direct costs were
included. Base-case and sensitivity analyses were performed.
Results: Base-case analysis results showed that at annual alendronate costs of $200 or less, osteoporosis screening followed
by treatment was cost-saving, resulting in lower total costs than no screening as well as more QALYs (10.6 additional
quality-adjusted life-days). When assuming alendronate costs of $400 through $800, screening and treatment resulted in
greater lifetime costs than no screening but was highly cost-effective, with ICERs ranging from $714 per QALY gained
through $13,902 per QALY gained. Probabilistic sensitivity analyses revealed that the cost-effectiveness of osteoporosis
screening followed by alendronate treatment was robust to joint input parameter estimate variation at a willingness-to-pay
threshold of $50,000/QALY at all alendronate costs evaluated.
Conclusions: Osteoporosis screening followed by alendronate treatment is effective and highly cost-effective for
postmenopausal women across a range of alendronate costs, and may be cost-saving at annual alendronate costs of $200
or less.
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Introduction
Osteoporosis affects approximately 10 million individuals in the
United States, most of whom are postmenopausal women [1,2]. It
is estimated that half of women over the age of 50 will sustain an
osteoporotic fracture during their lifetime [2], with potentially
severe consequences including mortality, chronic pain, mobility
limitation, and nursing home placement. Osteoporosis-related
costs in the U.S. were nearly $17 billion in 2005 [3], and are
projected to double or triple by 2040 [4]. The US Preventive
Services Task Force (USPSTF) recommends osteoporosis screen-
ing for women aged 65 and older, to identify individuals who may
be candidates for treatment [5].
Medical treatment of osteoporosis reduces fracture risk, and
multiple studies have demonstrated the cost-effectiveness of
osteoporosis treatment [6,7,8] and osteoporosis screening followed
by treatment [9,10]. Alendronate is a first-line medication for
osteoporosis treatment, and is among the most cost-effective
treatments for osteoporosis [6,10,11]. In 2008, alendronate became
available in generic form in the U.S., with a resulting drop in its cost
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and widening of the gap in price between alendronate and other
treatment options. Most published studies of the cost-effectiveness of
alendronate therapy have assumed pre-2008 costs; the cost of
alendronate has continued to drop since 2008; with prices currently
as low as approximately $84 annually at discount pharmacies [12].
The aim of this study was to evaluate the effect of various
alendronate costs on the cost-effectiveness of osteoporosis
screening and treatment.
Methods
We constructed a Monte Carlo microsimulation model of
osteoporosis screening followed by alendronate treatment com-
pared to no screening with treatment only if fracture occurs for US
women age 65 and older. The model estimates direct costs in 2010
US dollars, quality-adjusted life-years (QALYs), and incremental
cost-effectiveness ratios (ICERs) in units of cost per QALY gained
for osteoporosis screening followed by alendronate treatment. A
lifetime time horizon was used. We followed guidelines of the
Panel on Cost-Effectiveness in Health and Medicine [13], and ran
our analyses using TreeAge Pro Suite 2009 (TreeAge Software,
Williamstown, MA). Our methods are summarized briefly here –
more details can be found in a related paper in the Annals of
Internal Medicine on the cost-effectiveness of different screening
strategies for osteoporosis in postmenopausal women [14].
Model Development
General Structure. Figure 1 is a simplified schematic of the
model, in which cohorts of 65 year old community-dwelling
women are either screened with dual-energy x-ray absorptiometry
(DXA) of the femoral neck and lumbar spine, or not screened and
offered treatment only if an osteoporotic fracture occurs. Each
woman who tests positive for osteoporosis by DXA criteria (T-
score#22.5 at either the femoral neck or lumbar spine) is offered
alendronate treatment, and each who tests negative (i.e. T-
score.22.5) receives usual care only (calcium and vitamin D).
During each 3-month time period (cycle) in the model, the woman
may sustain a fracture of the hip, vertebra, or wrist; may survive or
die; may remain community-dwelling or enter a nursing home;
and may develop an alendronate adverse event. Prior fracture
history affects future fracture risk. Occurrence of a hip fractures
increases the probability of nursing home placement and short-
term death. Osteoporotic fractures, nursing home residence, and
alendronate-related adverse events incur direct costs and
‘‘disutility’’ (decrease in health-related quality of life). Individuals
continue cycling through the model until death. Table S1 shows
model parameter assumptions.
Screening. We modeled initiation of screening at age 65 with
DXA, with repeat screening every 5 years for individuals who test
negative. With repeat screening, individuals who did not have
osteoporosis at age 65 but who subsequently developed
osteoporosis as their BMD declined with age would be offered
treatment at the older age at which they are diagnosed. We used
65 as the screening initiation age for women in the absence of
additional risk factors in accordance with current guidelines from
the U.S. Preventive Services Task Force [5]. Initial DXA T-scores
for each simulated individual were assigned by sampling from
National Health and Nutrition Examination Survey (NHANES
III) femoral neck data for non-Hispanic white women [15], and
lumbar spine reference data for white women from a DXA
manufacturer (Hologic, Inc., Bedford, MA). We incorporated
correlations between sampled femoral neck and lumbar spine
values based on published data(R= 0.603); and modeled the
average annual change in T-scores at the lumbar spine and
femoral neck [15,16]. Constant, linear decrement in T-scores over
time was assumed.
Treatment. We assumed that women with positive DXA
results (T-scores#22.5) or who experienced a fracture of the hip,
vertebra (clinically detected), or wrist were offered treatment with
70 mg of alendronate once weekly. We assumed 5 years of
treatment [17,18] and medication compliance of 50% [19,20] in
base case analysis. We assumed that the 50% of individuals who
were initially compliant remained compliant with treatment for
the entire duration of recommended therapy unless they sustained
side effects requiring discontinuation. We assumed that 50% of
individuals were entirely noncompliant with treatment
recommendations, and that these individuals remained
noncompliant for the entire period or recommended therapy
unless they experienced an osteoporotic fracture. We assumed that
previously noncompliant individuals who sustained an
osteoporotic fracture had a 50% probability of becoming newly
compliant. We assumed that noncompliant individuals did not
Figure 1. Model Schematic. A simplified and partial representation of the full model.
doi:10.1371/journal.pone.0032879.g001
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incur the fracture reduction benefits or costs of alendronate
therapy. All individuals, whether receiving alendronate or not,
were assumed to be taking vitamin D and calcium, without
additional protection against fracture.
Fracture Rates. Fracture rates for women not on
alendronate treatment were based on Study of Osteoporotic
Fractures (SOF) data, with future fracture probability predicted as
a function of age, femoral neck or lumbar spine BMD, and history
of fracture [14,21]. We assumed that 35% of vertebral fractures
were clinically detected [22]. For women taking alendronate,
fracture relative risk was based on data from several published
clinical trials and a meta-analysis [23,24,25,26,27]. For individuals
who incurred a fracture, future fracture relative risk was predicted
using data for women with previous fractures [27]. For women
receiving alendronate treatment without a history of osteoporotic
fracture, we based future fracture relative risk on data for women
without previous fractures [23–26], using the fracture risk
estimates corresponding to the lower of the T-scores from the
lumbar spine or femoral neck.
We assumed a constant, linear decline in fracture risk reduction
benefit over 5 years after completion of alendronate treatment
[28].
Mortality Rates. We used US national vital statistics data for
baseline mortality rates [29]; and data on hip fracture-related
mortality from several published sources [30,31].
Nursing Home Characteristics. Nursing home admission
rates, length of stay, and mortality data were obtained from several
published sources [31,32,33,34].
Costs. We included direct costs of DXA screening ($97.71)
[35], alendronate therapy, fracture treatment, physician visits,
nursing home residence, and alendronate-related adverse events.
In separate base-case analyses, we evaluated annual alendronate
costs of $20, $40, $60, $80, $100, $200, $400, $600, and $800.
These costs were chosen to represent a spectrum of possible
alendronate annual costs, including a cost higher than the 2010
CMS Federal Upper Limit price for alendronate (approximately
$738) and costs lower than the current annual cost of alendronate
at discount pharmacies (approximately $84 ) [12]. Costs for
fracture-related treatment, other relevant medical services, and
nursing home stay were obtained from several sources [35–37].
We inflated costs to 2010 U.S. dollars using the US Consumer
Price Index for Medical Care [38]. We discounted future costs by
3% annually.
Utilities. We used data from a sample of older women in the
U.S. for baseline health state utilites [39]. We modeled disutility
from osteoporotic fractures, nursing home placement, and
alendronate adverse events using data from multiple published
sources [40,41,42,43,44,45,46]. We discounted future utility values
by 3% annually.
Adverse Events. We modeled medication adverse events of
esophagitis and esophageal ulceration with rates obtained from
clinical trials data [27].
Analyses
We performed base-case and sensitivity analyses separately for
each alendronate cost evaluated. Key parameter values used for
base-case analyses and the range of values used for sensitivity
analyses are shown in Table S1. Sensitivity analyses included
evaluation of different assumptions for key model parameters of
costs (higher than base-case); discount rate (5% annually instead of
3%); fracture risks (50% lower than base-case); and probability of
admission to a nursing home after hip fracture (30% instead of
60%). Additionally, probabilistic sensitivity analyses were per-
formed to evaluate the impact of joint input parameter uncertainty
on the model findings. For each base-case analysis and for the
sensitivity analyses of costs, discount rate, fracture risks, and
probability of nursing home admission, we ran the model with 1
million trials. For each probabilistic sensitivity analysis, we ran 500
simulations with 2,000 trials per simulation.
Model Validation
We compared the model’s fracture and life expectancy
predictions with published U.S. outcomes data.
Results
Model Validation
Our model predicted a mean life expectancy of 19.3 years for
65-year-old women who were not screened for osteoporosis. This
is similar to the U.S. National Vital Statistics figure of 19.8 years
reported for 65-year-old women in 2006 [47]. The model
predicted that 49% of 65-year-old women who were not screened
would experience at least one osteoporotic fracture during their
lifetime. Our model predicted that 28% of women would
experience a vertebral fracture; this figure matches that reported
in a prior study of older US women [48]. Our model predicted
that 24% of women would sustain a hip fracture during their
lifetime, and 17% would sustain a wrist fracture; these estimates
are higher than those reported in a study of Medicare beneficiaries
who sustained a fracture by age 90, which used data from 1986–
1990 [49]. However, women’s life expectancies have increased by
1.3 years since 1988, and 29% of women lived to be at least 90
years old in our modeling analysis; 17% of women in our analysis
experienced a hip fracture before age 90, close to the figure
reported by Barrett et al. [49].
Base-Case Analyses
Osteoporosis screening initiated at age 65 followed by
alendronate treatment was more effective than no screening with
treatment only if fracture occurs, resulting in 10.6 additional
quality-adjusted life-days. When assuming alendronate costs of
$200 or less, osteoporosis screening and treatment was cost-saving,
resulting in lower total costs than no screening as well as more
QALYs (Table 1). Lifetime direct cost savings ranged from $171 to
$343 when assuming alendronate annual costs of $200 or $20,
respectively. When assuming alendronate costs of $400, $600, or
$800, screening and treatment resulted in greater lifetime costs
than no screening but was highly cost-effective, with ICERs
ranging from $714 per QALY gained to $13,902 per QALY
gained when assuming annual alendronate costs of $400 or $800,
respectively (Table 1).
Sensitivity Analyses
Table 2 shows results (ICERs and cost savings) from sensitivity
analyses of assumptions for costs, discount rate, fracture risks, and
probability of nursing home admission after hip fracture. In
general, these results were similar to base-case analysis findings in
demonstrating the value of osteoporosis screening followed by
alendronate treatment across a range of alendronate annual costs.
However, ICERs or cost savings associated with different
alendronate costs varied. When assuming 50% lower fracture
risks, screening and treatment remained cost-effective across the
range of costs evaluated, but with higher ICERs than in base-case
analysis; additionally, none of the alendronate costs evaluated were
associated with cost savings. When assuming nursing home
admission probability of 30% after hip fracture instead of 60%,
screening and treatment remained highly cost-effective, but with
ICERs higher than in base-case analysis; additionally, the annual
Alendronate Cost-Effectiveness
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cost at which alendronate became cost-saving was $40 instead of
$200. When assuming high costs for fracture-related treatment,
nursing home care, and DXA, screening and treatment remained
highly cost-effective, but with ICERs higher than in base-case
analysis; additionally, the cost at which alendronate became cost-
saving was $100 instead of $200. When assuming a discount rate
of 5% instead of 3%, results were similar to base-case analysis,
with screening and treatment becoming cost-saving at annual
alendronate costs of $200 or lower.
Probabilistic sensitivity analyses revealed that the cost-effective-
ness of osteoporosis screening followed by alendronate treatment
was relatively robust to variations in input parameter estimates at a
willingness-to-pay threshold of $50,000/QALY for all alendronate
costs evaluated (Figure 2). When assuming annual alendronate
costs of $100 or less, the probability that osteoporosis screening
followed by alendronate treatment was cost-effective was 95%.
The probability that screening followed by alendronate treatment
was cost effective remained high at 84% when assuming an annual
alendronate cost of $800.
Discussion
Our analyses demonstrated that osteoporosis screening followed
by alendronate treatment is effective and highly cost-effective for
women aged 65 and older across a wide range of alendronate
costs; and potentially cost-saving at annual alendronate costs of
$200 or less, depending on assumptions about fracture risk,
nursing home admission probability after hip fracture, and health
care costs. Sensitivity analyses showed that the value (cost-
effectiveness) of alendronate treatment for all alendronate costs
evaluated was relatively robust to key model parameter uncer-
tainty; but the price at which alendronate becomes cost-saving is
sensitive to the parameters specified above. These results indicate
that osteoporosis screening followed by alendronate treatment is
an advantageous use of healthcare resources for women age 65
and older, that can be expected to improve health outcomes and
may result in potential cost savings when alendronate annual costs
are $200 or less, as is currently the case at discount pharmacies. As
the cost of alendronate continues to fall, the value and potential for
cost savings for the U.S. healthcare system resulting from
osteoporosis screening of older women followed by alendronate
treatment can be expected to increase, assuming appropriate
selection of candidates for treatment. This is a significant finding,
given how few preventive services can result in cost savings
[50,51].
Our model has several limitations. First, our analyses did not
incorporate the costs of added life days from osteoporosis
screening. However, the costs of added life days would likely be
small as the age of death was very similar in the screening followed
by treatment and no screening model arms. Second, our analysis
assumed that only women with DXA T-scores in the osteoporotic
range would be offered treatment, in accordance with evidence
that treatment of women with osteopenia (low bone mass) is not
Table 1. Base-Case Analysis Results, Various Alendronate
Costs.
Alendronate Cost ($)
Incremental Cost-Effectiveness
Ratio ($/QALY)a
20 Cost-saving: $343b
40 Cost-saving: $324b
60 Cost-saving: $305b
80 Cost-saving: $286b
100 Cost-saving: $266b
200 Cost-saving: $171b
400 $712
600 $7307
800 $13,902
aIncremental cost-effectiveness of osteoporosis screening followed by
alendronate treatment, compared to no screening with treatment only if
fracture occurs; in 2010 US dollars per quality-adjusted life-year (QALY).
bLifetime direct costs saved.
doi:10.1371/journal.pone.0032879.t001
Table 2. Sensitivity Analysis Results; Costs, Discount Rate, Fracture Risk, Nursing Home Probability.
Alendronate Cost ($) Incremental Cost-Effectiveness Ratio ($/QALY)
a
High Costs Scenariob High Discount Rate Scenarioc
Low Fracture Risk
Scenariod
Low Nursing Home Probability
Scenarioe
20 Cost-saving: $116f Cost-saving: $275f $5483 Cost-saving: $28f
40 Cost-saving: $97f Cost-saving: $258f $6728 Cost-saving: $9f
60 Cost-saving: $77f Cost-saving: $241f $7973 $362
80 Cost-saving: $58f Cost-saving: $223f $9218 $1047
100 Cost-saving: $39f Cost-saving: $206f $10463 $1733
200 $1948 Cost-saving: $119f $16688 $5161
400 $8543 $2561 $29138 $12018
600 $15138 $10638 $41588 $18874
800 $21733 $18715 $54037 $25731
aIncremental cost-effectiveness of osteoporosis screening followed by alendronate treatment, compared to no screening with treatment only if fracture occurs; in 2010
US dollars per quality-adjusted life-year (QALY).
bHigh fracture-related, nursing home, and dual-energy x-ray absorptiometry costs (high values of the sensitivity analysis range for costs shown in Table S1).
cDiscount rate for future costs and health state utilities of 5% annually.
dFracture risks (hip, vertebral, and wrist) 50% lower than in base-case analysis.
eProbability of nursing home admission after hip fracture of 30%.
fLifetime direct costs saved.
doi:10.1371/journal.pone.0032879.t002
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cost-effective [52]. However, if screening leads to inappropriate
treatment of individuals at lower risk for osteoporotic fracture, it’s
cost-effectiveness and potential cost savings would be lessened.
Additionally, we did not model all potential adverse events of
alendronate treatment, including arthalgias, myalgias, osteonecro-
sis of the jaw, or atypical femoral neck fractures; such adverse
events may require additional physician visits, labwork, or
discontinuation of medication. However, osteonecrosis of the jaw
and atypical femoral neck fractures are rare reported adverse
events, and their association with alendronate treatment is still
under investigation. Moreover, the effectiveness and adherence
with generic bisphosphonate therapy may be lower than with
proprietary formulations [53]. If this is the case, and adherence or
fracture risk reduction with generic alendronate is lower than our
model assumptions, generic alendronate therapy would be less
cost-effective than our findings suggest. Finally, our model
parameter inputs were primarily based on data from white
women, and thus our results may be less applicable to women of
other races.
In conclusion, our analyses indicate that osteoporosis screening
followed by alendronate treatment is highly cost-effective for
women aged 65 and older when assuming annual alendronate
costs of $400 through $800, and potentially cost-saving when
assuming annual alendronate costs of $200 or less, depending on
key parameter assumptions. Thus, osteoporosis screening followed
by alendronate treatment in appropriately selected patients
Figure 2. Probabilistic Sensitivity Analysis Cost-Effectiveness Acceptability Curves.
doi:10.1371/journal.pone.0032879.g002
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represents an excellent healthcare value, and this important
preventive health service should be promoted. Although our
analyses were limited to alendronate, other osteoporosis treat-
ments with similar effectiveness and costs may be expected to be
similarly cost-effective. For example, other available oral bisphos-
phonates (e.g. risedronate) may be similarly cost-effective if costs of
the medication were to decrease. However intravenous bisphos-
phonates, which have additional costs for the infusions, different
adverse event profiles, as well as different fracture reduction
outcomes would not be expected to have similar cost-effectiveness
to alendronate. This would apply to other osteoporosis medica-
tions that have different costs, adverse event profiles, adherence
patterns, and routes of administration.
Future research should evaluate the cost-effectiveness of ‘‘real-
world’’ osteoporosis screening and treatment practices, in which
some patients will be inappropriately selected for treatment.
Furthermore the effects of assuming treatment duration longer
than 5 years or a drug holiday should be examined. However,
assuming appropriate selection of individuals for treatment,
osteoporosis screening followed by alendronate treatment in
women aged 65 and old represents a superb healthcare value
across the variety of alendronate costs evaluated.
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